Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”

Pestana, Mafalda; Caldeira, Margarida Brito; Cabete, Joana

doi:10.1007/s40257-022-00694-z

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Maintenance therapy targets of 3-7 mg/L, $6-7 mg/L, and 2-5 mg/L are suggested in rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis, respectively. 62,[107][108][109]111,112,114,117,118,120,133,134 Area(s) of Future Research An SC formulation of infliximab has recently become available, altering the PK profile of infliximab in patients. This necessitates a reevaluation of target concentrations for this specific formulation because trough concentrations are higher during standard SC therapy compared with IV therapy.…”

Section: Clinical Recommendationsmentioning

confidence: 99%

“…Because of these similarities between perianal hidradenitis suppurativa and CD, some authors expressed doubt about using a target regardless of the location of hidradenitis suppurativa lesions and wondered if higher infliximab concentrations would be necessary in fistulizing perianal hidradenitis suppurativa. 133…”

Section: Defining the Therapeutic Targetmentioning

confidence: 99%

“…Maintenance therapy targets of 3–7 mg/L, ≥6–7 mg/L, and 2–5 mg/L are suggested in rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis, respectively. 62,107–109,111,112,114,117,118,120,133,134…”

Section: Defining the Therapeutic Targetmentioning

confidence: 99%

See 2 more Smart Citations

Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Alsoud,

Moes,

Wang

et al. 2024

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

Background: Infliximab, an anti–tumor necrosis factor monoclonal antibody, has revolutionized the pharmacological management of immune-mediated inflammatory diseases (IMIDs). This position statement critically reviews and examines existing data on therapeutic drug monitoring (TDM) of infliximab in patients with IMIDs. It provides a practical guide on implementing TDM in current clinical practices and outlines priority areas for future research. Methods: The endorsing TDM of Biologics and Pharmacometrics Committees of the International Association of TDM and Clinical Toxicology collaborated to create this position statement. Results: Accumulating data support the evidence for TDM of infliximab in the treatment of inflammatory bowel diseases, with limited investigation in other IMIDs. A universal approach to TDM may not fully realize the benefits of improving therapeutic outcomes. Patients at risk for increased infliximab clearance, particularly with a proactive strategy, stand to gain the most from TDM. Personalized exposure targets based on therapeutic goals, patient phenotype, and infliximab administration route are recommended. Rapid assays and home sampling strategies offer flexibility for point-of-care TDM. Ongoing studies on model-informed precision dosing in inflammatory bowel disease will help assess the additional value of precision dosing software tools. Patient education and empowerment, and electronic health record–integrated TDM solutions will facilitate routine TDM implementation. Although optimization of therapeutic effectiveness is a primary focus, the cost-reducing potential of TDM also merits consideration. Conclusions: Successful implementation of TDM for infliximab necessitates interdisciplinary collaboration among clinicians, hospital pharmacists, and (quantitative) clinical pharmacologists to ensure an efficient research trajectory.

show abstract

Section: Clinical Recommendationsmentioning

confidence: 99%

Section: Defining the Therapeutic Targetmentioning

confidence: 99%

See 1 more Smart Citation

Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Alsoud,

Moes,

Wang

et al. 2024

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

show abstract

Author’s Reply to Pestana et al. Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”

Alavi

Raffals

2022

Am J Clin Dermatol

View full text Add to dashboard Cite

Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments

Chiang,

Alhusayen

2024

J Cutan Med Surg

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that presents as painful, deep-seated nodules, sinus tracts, and abscesses in about 1% of the population. Although the pathogenesis of HS is not perfectly understood, it is generally recognized to be caused by a combination of genetic, endocrine, environmental, and microbiological factors. The treatment principles of HS focus on decreasing the microbial load with antibiotics and/or modulating the host immune response to reduce inflammation. The treatment of adults with moderate-to-severe HS has significantly changed recently with the development of new biological medications and immunomodulators. While previously the mainstay of treatment of moderate-to-severe HS was adalimumab, a biologic tumour necrosis factor α inhibitor, the evidence for the use of other treatment classes such as interleukin (IL)-17 inhibitors, IL-1 inhibitors, and Janus kinase inhibitors has been growing. The goal of this review article is to review the available evidence that supports the efficacy and safety of biologics and small molecule immunomodulator treatments to treat adults with moderate-to-severe HS.

show abstract

Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”

Cited by 3 publications

References 10 publications

Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Author’s Reply to Pestana et al. Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”

Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments

Contact Info

Product

Resources

About